NAVIGATING THE HEALTH TECHNOLOGY ASSESSMENT PROCESS AROUND THE WORLD

Health technology assessment (HTA) is increasingly playing an important role in informing reimbursement and pricing decisions across the world. This forum will present the results from a global survey assessing current methods in health technology assessment and its application in reimbursement decisions; will present models of the health-care decision making processes specifically for coverage and reimbursement of emerging new technologies, and will introduce the Global Health Care Systems Road Map, an initiative to provide an overview of country-specific health care delivery systems, reimbursement and pricing approval processes, using the examples of Canada and France.

Moderator: Jalpa A. Doshi PhD, Co-Chair HTA and Good Research Practice for Reimbursement Decisions Working Group and Research Assistant Professor of Medicine, General Internal Medicine, Director, Economic Evaluations Unit, Center for Evidence-Based Practice, University of Pennsylvania, Philadelphia, PA, USA

Speakers:
Jennifer Stephens PharmD, Co-Chair HTA and Good Research Practice for Reimbursement Decisions Working Group and Clinical Director, PharMerit International, Bethesda, MD, USA
Karl Matuszewski, MS, PharmD, HTA of Emerging New Technologies Working Group and Senior Director, Clinical Knowledge Service Clinical Practice Advancement Center, University HealthSystem Consortium, Oak Brook, IL, USA
W. Neil Palmer, Global HTA Used in Health Care Reimbursement Working Group and Vice President, Pricing & Reimbursement, RTI Health Solutions, Ottawa, ON, Canada;
Annie Chicoye PhD, Global HTA Used in Health Care Reimbursement Working Group and Senior Principal, Aremis Consultants, Neuilly sur Seine, France

Click here for presentation

Pharmacoeconomic and Outcomes Research Fellowship Standards

This Forum provides an opportunity to discuss the upcoming publication of the Task Force report “Joint ACCP and ISPOR Guidelines for Pharmacoeconomic and Outcomes Research Fellowship Training Programs”.  Several PEOR fellowship mentors and their fellows will briefly discuss their experiences and its relationship to the Fellowship Guidelines.  A floor discussion will be open to all participants, including fellows, preceptors of fellows, academics and other interested parties, to meet and share their thoughts and ideas about Pharmacoeconomic fellowships.

Moderator: Alan Bakst, PharmD, MBA, Chair, ISPOR Fellowship Standards Task Force and Senior Director, Global Health Economics and Reimbursement, Baxter Healthcare Corporation, McGaw Park, Il, USA

Speakers:
Svetlana Denevich PharmD, Pharmacoeconomics and Outcomes Research Fellow, Abt Associates, Lexington, MA, USA
Shiraz Gupta PharmD, Manager, Global Health Economics & Outcomes Research, Abbott Laboratories, Abbott Park, Il, USA
A. Simon Pickard, PhD, Assistant Professor, Pharmacy Practice & Pharmacy Administration, Assistant Director, Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois, Chicago, IL, USA
Prabashni Reddy RPh, MS, PharmD, Director of the Center for Drug Policy, Partners Healthcare, Charlestown, MA, USA
Robert Wittenberg PharmD, Fellow, University of Illinois at Chicago & TAP Pharmaceutical Products, Inc., Northbrook, IL, USA

Assessment, Determinants & Economics of Medication Compliance & Persistence

Moderator: Femida Gwadry-Sridhar PhD, RPh, MSc, ISPOR Determinants of Compliance & Persistence Working Group Chair & Assistant Professor, University of Western Ontario & Mc Master University, Director CCR-Net & Director Health Informatics Lawson Health Research  Institute, London, ON, Canada

Prospective Assessment of Medication Compliance & Persistence
Compliance research requires an understanding about the best methodology to conduct trials including, randomized controlled clinical trials setting, observational cohort, and quasi- experimental.  Key considerations for researchers regarding the design, analysis and reporting of results of such trials will be reviewed.

Speaker: Femida Gwadry-Sridhar PhD, RPh, MSc on behalf of the ISPOR Analyses Standards Leadership Group & Assistant Professor, University of Western Ontario & Mc Master University, Director CCR-Net & Director Health Informatics – Lawson , London, ON, Canada

The Costs of Non-compliance
Medication non-compliance and failure to persist with treatments have substantial economic consequences.  A systematic review of the literature will aim to provide the basis for a cost of ‘illness’ study for selected diseases.

Speaker: Judith Shinogle MSc, PhD, ISPOR Economics of Compliance & Persistence Working Group Chair & Assistant Professor, Department of Health Services Administration, University of Maryland College Park School of Public Health

Determinants of Compliance & Persistence
A systematic review is complete. We  assessed the effectiveness of compliance-enhancing interventions, founded on key "determinants" of non-compliance.  The results for selected disease areas will be presented.

Speaker: Femida Gwadry-Sridhar PhD, RPh, MSc, ISPOR Determinants of Compliance & Persistence Working Group Chair & Assistant Professor, University of Western Ontario & McMaster University, Director CCR-Net & Director Health Informatics- Lawson-, London, ON, Canada

Discussion

Design and Analysis of Non-Randomized Studies of Treatment Effects using Secondary Databases

This forum will present the major issues of design, analysis, and interpretation of findings from therapeutic effectiveness studies using secondary databases. Your comments and input are invited.

Moderator: Michael Johnson PhD, Co-Chair, Good Research Practices for Retrospective Database Analysis Task Force and Associate Professor, University of Houston, College of Pharmacy, Houston, TX USA

Speakers:
Marc Berger, MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
Muhammad Mamdani, PharmD, MA, MPH, Director, Applied Health Research Centre (AHRC), Li Ka Shing Knowledge, Institute of St. Michael's Hospital, Canada and Associate Professor, Department of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Canada
Colin Dormuth, ScD, Assistant Professor, Dept. of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia; Chair of Pharmacoepidemiology Group, Therapeutics Initiative, British Columbia, Canada
William Crown, PhD, President, i3Innovus, Waltham, MA, USA
Bradley Martin PhD, RPh, PharmD, Assoc. Prof. and Division Chair, College of Pharmacy, University of Arkansas for Medical Sciences, Department of Pharmacy Practice, Little Rock, AR USA
Emily Cox, PhD, Senior Director of Research, Express Scripts, Saint Louis, MO, USA

Good Research Practices On Economic Data Transferability

The draft final report and recommendations on best practices in transferability of economic data in health economic evaluations will be discussed.  Several factors may limit the generalizability of economic (i.e. resource, cost and utility) data, including differences in relative prices, practice patterns, availability of health care resources and community values of health states. This session will focus on issues identified by ISPOR members concerning the draft Task Force Report now at the ISPOR website. These issues include defining key variable economic data, guidelines for acceptance of data from outside a country while considering existing national guidelines, and directions for future research.

Speakers:
Michael Drummond PhD, Professor of Health Economics, University of York, Centre for Health Economics, Heslington, York, UK
Shelby Reed PhD, RPh, Assistant Research Professor, Duke Clinical Research Institute, Durham, NC, USA
Mark Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK

Quality Improvement in Cost-Effectiveness Research & Use

This session will focus on facilitating the improvement of health care economic evaluation research and its use in making health care policy.  Updates on the present and future of global guidelines, statistical problems in cost effectiveness research and ideas for improving the science, the prevalence and scope of quality guidelines in journals & publications, and barriers to use of cost effectiveness data by decision-makers and patients will be presented by the ISPOR QICER Task Force.

Speaker: William McGhan PhD, PharmD, Professor of Pharmacy & Health Policy, University of the Sciences, Philadelphia, PA USA

Overview of Decision Analysis and its Application

A decision tree analysis is one of the most systematic tools of decision making in the health care practice setting. This ISPOR Student Educational Forum will provide a basic overview of the key terminology in decision analysis. During this forum, students will bridge the gap between understanding pharmacoeconomics concepts and the application of decision analysis.

Moderators: Zeba Khan, PhD, Executive Director, Pricing, General Medicines, Novartis Pharmaceuticals, East Hanover, NJ USA, ISPOR Student Network Faculty Advisor; Seina P Lee, PharmD, MS, Outcomes Research Fellow, Ortho-McNeil Janssen Scientific Affairs,LLC/Department of Health Policy, Thomas Jefferson University, ISPOR Student Network Chair 2007-2008

Speaker: Grant H. Skrepnek PhD, Assistant Professor, Pharmacy Practice and Science University of Arizona College of Pharmacy